<analysis>
**A note on threat numbering.** The adversary list runs two threats together under item 1: the S-1 threat and the KYC/HIPAA threat. That makes five distinct threats. I list them in order with explicit names below so each roll resolves unambiguously.

**Action 1 (alignment).** This action has four linked parts.
- **Environments.** Repairing two failed families and reaching 75% in one month is plausible, but compute competes with the frozen Q1 cycle.
- **Baseline.** The fresh-probe and clean-honeypot baseline is routine once the environments exist.
- **Probe rule.** The narrowed, prospective-only rule answers the interpretability teams' objection. It still cannot be *adopted* in March, because adoption belongs to the Q2 RSP revision. The best March outcome is that it is placed on the revision agenda.
- **Securities counsel.** Adding a risk factor during SEC comment review is the hardest part. That risk is modelled in Threat 1, so it is not double-counted here.
- **Overall.** Multiple dependencies, and leadership has twice deprioritised this work. Moderately high failure.

**Action 2 (H.R. 1412).**
- **Easy parts.** Supplying amendment text and an NDAA provision is easy.
- **Committee calendar.** Getting House Science to schedule a markup in March, for a bill introduced on 24 February, is unlikely on base rates. Most bills never get a markup, and hearings usually come first.
- **Anthropic's posture.** The low-profile shift is within leadership's discretion and probably accepted.
- **Critics.** Public Citizen may not consult Claude at all.
- **NDAA timing.** FY2028 NDAA markups are around May–June, so March yields only a draft held by offices.
- **Obernolte (per judge feedback).** He co-sponsors while pushing preemption elsewhere. Any NDAA outreach to his office will surface that tension.
- **Industry reaction (per judge feedback).** Trade groups such as NetChoice and the Chamber, and possibly OpenAI's policy team, will likely align with Cruz's preemption stance.

**Action 3 (KYC and hospital).**
- **Building the layer.** Claude Code can write the layer quickly. Security-critical access control built largely by the model will almost certainly get an independent review. That specific stall is covered by Threat 2.
- **Letter of intent.** Signing an LOI with an interested health system is feasible.
- **HIPAA eligibility.** This is checkable within the month.
- **Execution risk.** Scope creep, and Glasswing leads who have blocked this twice before.

**Action 4 (V5 kit and bio).**
- **Response kit.** Easy, internal work.
- **Six-lab offer.** Sending the offer is easy. Activating sharing is not; Threat 4 covers that.
- **Taxonomy.** Its timing depends on Gemini 4 GA, which is plausibly this month.
- **Bio.** Cutting false positives below 3% quickly risks overfitting to the red-team set.

**Action 5 (science and states).** The release is already on track. The compliance memo and DPA template are low-risk deliverables. State agreements are not expected this month.

**Action 6 (stable identity).** A small internal experiment on existing compute is feasible. Risks are compute contention, noisy merge results, or research leads reallocating the compute.

**Compute timeline (per judge feedback).** Anthropic's next frontier pretraining run is about 1e28 FLOP. It is scheduled to start in late Q2 2027 on new capacity (Akamai and Google TPU tranches, plus about 1.5 GW of new US capacity coming online around May–July). OpenAI's Stargate Abilene expansion supports a comparable run in the same period. Frontier compute should therefore reach about 1e28 in mid-2027 and around 5e28 by early 2028, which keeps the trajectory consistent with ASI arriving by December 2030.
</analysis>

<action_odds>
Action 1 [Alignment Q2 case and counsel unblock]: P(failure) 55%. Reason: there are four dependent parts, compute competes with the Q1 cycle, and leadership has twice deprioritised this work. Adoption of the rule can at best be queued for Q2 this month. The S-1 amendment risk is left to Threat 1.

Action 2 [H.R. 1412 hardening and NDAA route]: P(failure) 55%. Reason: the text deliverables are easy, but a March markup a month after introduction is below base rate, critics' offices may not engage, and the NDAA route can only be a draft this early.

Action 3 [KYC layer and hospital LOI]: P(failure) 45%. Reason: the build itself is feasible, and the LOI with an interested system is plausible. Glasswing leads have blocked this twice, and the scope is large for one month. Independent-review and HIPAA stalls are left to Threat 2.

Action 4 [V5 kit, FMF offer, bio screen]: P(failure) 35%. Reason: the kit and the offer are internal and easy. Risk comes mainly from bio tuning quality and from Gemini 4 timing. Channel activation and bio re-review stalls are left to Threat 4.

Action 5 [Science release and state workforce]: P(failure) 20%. Reason: the release is already on track and the memos and templates are routine. State deals are not expected in March in any case.

Action 6 [Stable-identity drift experiment]: P(failure) 30%. Reason: it is small and internal on existing compute, but compute contention and the chance of inconclusive merge results are real.
</action_odds>

<threat_odds>
Threat 1 [S-1 amendment backfires or stalls the flip]: P(materialises) 45%. Adversary suggested 50%. Counsel resisting a new risk factor mid-review is quite likely given its track record, but the full compound (media spin at the flip plus the probe rule reduced to "guidance") is somewhat less than even.

Threat 2 [KYC layer fails its own review, hospital hits HIPAA and data-flow walls]: P(materialises) 50%. Adversary suggested 55%. Independent review of security-critical code written by Claude is close to standard practice after the obfuscation result. The hospital CISO objecting to usage logging is plausible but not certain, and an infrastructure-only scope softens the HIPAA issue.

Threat 3 [NDAA preemption counter-move and "chatbot-written law" redux]: P(materialises) 30%. Adversary suggested 40%. The NDAA markup is still months away, so a preemption rider this month is only at the signalling stage. A second authorship news cycle needs a reporter to act on the new policy within weeks.

Threat 4 [Six-lab channel and DNA screen stall]: P(materialises) 55%. Adversary suggested 50%. Microsoft's counsel review is already pending in the world state, and cross-competitor sharing is slow by default. Demanding a second red-team after tuning against the first red-team set is the standard biosecurity response.

Threat 5 [DeepSeek V5 drop plus open-weight hospital ransomware wave]: P(materialises) 25%. Adversary suggested 30% for release and 20% for the campaign. A March V5 release is plausible since it is overdue and benchmarks have leaked, but the timing is uncertain. An attributed multi-hospital campaign in the same month is much less likely. It occurs only on a very low roll (<7); otherwise materialisation means the release alone.
</threat_odds>
